Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Next Previous
Trial Profile

A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safinamide (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Meiji Seika Pharma

    • Most Recent Events

    • 15 Sep 2022 Results of post hoc analysis assessed long term effects of safinamide published in the Journal of Neural Transmission
    • 20 Sep 2019 Results presented in a Newron Pharmaceuticals media release.
    • 20 Sep 2019 According to a Newron Pharmaceuticals media release, based on the data from a Phase II/III study (ME2125-3), this Phase III study (ME2125-4), as well as global clinical trials, Eisai Co., and Meiji Seika Pharma Co., Ltd received the manufacturing and marketing approval for Equfina TABLETS in Japan for the indication of improvement of wearing-off phenomenon in patients with Parkinsons disease under treatment with a drug containing levodopa.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top